Biogen Inc. Common Stock (BIIB)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$2.00 (-1.08%)Past Day

About

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Key Insights

  • Share Price

    $183.03

  • Market Cap

    $26.66 Billion

  • Total Outstanding Shares

    145.66 Million Shares

  • Total Employees

    7,570

  • Dividend

    No dividend

  • IPO Date

    September 17, 1991

  • SIC Description

    Biological Products, (no Disgnostic Substances)

  • Homepage

    https://www.biogen.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

July 1, 2023 to June 30, 2024
MetricValue
Net Cash Flow, Continuing$-692.40 Million
Net Cash Flow From Investing Activities, Continuing$-1.99 Billion
Net Cash Flow From Financing Activities$-482.30 Million
Net Cash Flow From Investing Activities$-1.99 Billion
Exchange Gains/Losses$-16.50 Million
Net Cash Flow From Operating Activities, Continuing$1.78 Billion
Net Cash Flow From Financing Activities, Continuing$-482.30 Million
Net Cash Flow$-708.90 Million
Net Cash Flow From Operating Activities$1.78 Billion

Income Statement

July 1, 2023 to June 30, 2024
MetricValue
Income/Loss From Continuing Operations After Tax$1.16 Billion
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Net Income/Loss Attributable To Noncontrolling Interest$-1.00 Million
Net Income/Loss Attributable To Parent$1.16 Billion
Net Income/Loss Available To Common Stockholders, Basic$1.16 Billion
Income Tax Expense/Benefit$156.30 Million
Income/Loss From Continuing Operations Before Tax$1.31 Billion
Selling, General, and Administrative Expenses$2.53 Billion
Operating Income/Loss$1.31 Billion
Other Operating Expenses$3.46 Billion
Income Tax Expense/Benefit, Deferred$-182.00 Million
Revenues$9.67 Billion
Net Income/Loss$1.16 Billion
Costs And Expenses$8.36 Billion
Preferred Stock Dividends And Other Adjustments$0.00
Gross Profit$7.31 Billion
Benefits Costs and Expenses$8.36 Billion
Interest Expense, Operating$265.80 Million
Operating Expenses$5.99 Billion
Diluted Earnings Per Share$7.94
Basic Earnings Per Share$7.97
Diluted Average Shares$290.80 Million
Basic Average Shares$290.20 Million
Cost Of Revenue$2.37 Billion

Balance Sheet

July 1, 2023 to June 30, 2024
MetricValue
Current Liabilities$3.11 Billion
Other Current Assets$4.60 Billion
Fixed Assets$3.25 Billion
Liabilities$10.91 Billion
Noncurrent Liabilities$7.81 Billion
Inventory$2.51 Billion
Other Current Liabilities$2.53 Billion
Accounts Payable$354.50 Million
Other Non-current Assets$8.21 Billion
Other Non-current Liabilities$1.51 Billion
Noncurrent Assets$19.70 Billion
Equity$15.89 Billion
Intangible Assets$8.23 Billion
Liabilities And Equity$26.80 Billion
Equity Attributable To Noncontrolling Interest$0.00
Wages$228.30 Million
Assets$26.80 Billion
Long-term Debt$6.29 Billion
Equity Attributable To Parent$15.89 Billion
Current Assets$7.11 Billion

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
News ArticlesAbout UsPrivacy Policy & Cookies Information

ⓒ2024 Financhle. All Rights Reserved.